In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
List view / Grid view
Filter the results
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
Researchers have developed a new screening technique called biological activity-based modelling to identify drug candidates.
According to a new report, the high-throughput screening market will increase at a CAGR of 11.5 percent from 2020 to 2025.
Between January and October 2020, scientists globally have published more than 87,000 papers about the coronavirus.
Vascor (bepridil) could be used to treat COVID-19, according to a new study which screened drugs to repurpose against SARS-CoV-2.
A novel nanotherapy can decrease intestinal inflammation and shrink lesions in rodent models of Crohn's disease, a study has shown.
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.